Loading...
Options B.R.O.
Example search prompt
Example search prompt
Example search prompt
Example search prompt
The Lupin share price was in focus in the stock market today after the company received a key approval from the US health regulator. Shares of the Mumbai-based pharmaceutical major moved 1.5% higher, tracking fresh developments from the United States market.Let’s break down what happened, why it ...
Stocks to Watch Today on February 25 are led by a major enhancement in investment delegation for Power Grid Corporation, fresh US regulatory approvals in the pharmaceutical sector, a government stake sale in Indian Railway Finance Corporation, robust quarterly earnings from select industrial comp...
Q3 FY26 Performance SnapshotThe Indian pharma sector delivered a steady Q3 FY26, with performance largely driven by domestic strength.Sales Growth: +13% YoYOperating Profit: +12% YoYPAT Growth: +1% YoYWhile revenue and operating profit expanded in tandem, net profit growth remained muted due to m...
When markets opened after the announcement of Lupin Q3 results, the numbers spoke for themselves.It wasn’t just growth. It was broad-based strength. From the US to emerging markets, the company delivered solid expansion. And that’s what made this quarter stand out.In Q3 FY26, Lupin Q3 net profit ...
The Q3 Result 2026 season is hitting its final stretch. And today is one of the busiest days of the quarter.More than 400 companies are set to announce their Q3 Result for the quarter ended December 31, 2025, on February 12. From FMCG to defence, from oil & gas to hospitality, the earnings bo...
Lupin has taken a significant strategic step to strengthen its presence in the fast-growing diabetes and obesity treatment space by entering into an exclusive license, supply, and distribution agreement with China-based Gan & Lee Pharmaceuticals. The partnership brings Bofanglutide, a novel f...
The stock market is buzzing with fresh developments, and several companies are making headlines with key updates. From regulatory inspections to big-ticket orders and strategic acquisitions, these names could remain in focus in today’s trade.Let’s break down the stories shaping market sentiment.M...
Market PerformanceThe Nifty Pharma Index rose 1.9% during intraday trades on Wednesday, marking a strong relief rally in the Indian stock market.Opening level: 21,803.45Previous close: 21,753.50Intraday high: 22,171.05Leading the gains were Alkem Laboratories, Zydus Lifesciences, Laurus Labs, and...
Market PerformanceLupin share price was trading marginally higher at ₹1,946.30 per share on the BSE during Tuesday’s session, following the announcement of a strategic partnership with Switzerland-based Sandoz Group AG.Main NewsMumbai-headquartered Lupin Ltd has entered into an agreement with San...
The Indian stock market experienced a steep decline on Friday, August 1, as both benchmark indices — Sensex and Nifty — closed notably lower. The selloff was triggered by multiple global and domestic concerns, leading to a massive erosion in investor wealth.Market PerformanceSensex fell 586 point...
Market PerformancePharma stocks witnessed a sharp sell-off on Friday, triggered by new developments from the United States that rattled investor sentiment.The Nifty Pharma index fell over 2.8%, marking its third consecutive day of decline.Sun Pharma led the fall with a 4% drop, becoming the worst...
Market PerformanceIndian pharmaceutical stocks traded with mild gains on July 9 despite unsettling geopolitical developments. The Nifty Pharma Index was trading at 22,252.50, up 0.4% as of 9:25 a.m.Month-to-date performance: The Nifty Pharma index gained 0.6% so far in July.Year-to-date movement:...
Market OverviewOn July 8, the broader market experienced a steep downturn as the midcap and smallcap indices declined sharply, underperforming the benchmark indices.The Nifty Midcap index continued its losing streak for the third straight session.The Nifty Smallcap index also slipped into the red...
Market PerformanceOn July 8, Indian pharmaceutical stocks experienced a notable dip in early trade as global trade tensions escalated. The Nifty Pharma index slipped nearly 1%, hovering around 22,159 during morning hours.This marked the second straight day of losses for the index, after an extend...
Market PerformanceLupin's share price experienced an uptick in early trading on July 2, following a key regulatory milestone.At 09:20 AM, Lupin shares were trading at ₹1,969.70, up by ₹8.40 or 0.43% on the BSE.The stock is currently:18.05% below its 52-week high of ₹2,403.45 (hit on January 2, 20...
Market PerformanceDespite a weak broader market on June 12, Nifty Pharma outshone as the only sectoral gainer, climbing nearly 1% to 22,243 in morning trade.This uptrend in pharma shares was primarily driven by easing global trade concerns after U.S. President Donald Trump's announcement regardin...
Market PerformanceThe Nifty Pharma Index witnessed a sharp correction in Monday's early trade, sliding over 2% amid renewed concerns over US drug pricing.The index opened at 20,949.70It dropped to an intraday low of 20,576.05This marked a decline of more than 2% from the previous close of 21,071....
Market PerformanceThe Nifty Pharma Index plunged 1.92% in morning trade on Tuesday, sliding from Monday's close of 21,775.75 to an intraday low of 21,359.30.Opening level: 21,672.85Previous Close: 21,775.75Intraday low: 21,359.30Total dip: Approx. 2%This marked a notable fall in pharmaceutical st...
Market OverviewOn April 11, 2025, pharmaceutical shares witnessed a notable upswing following the temporary suspension of reciprocal tariffs by the United States. This development helped reduce recession-related concerns and contributed to optimism in the pharma sector. The Nifty Pharma index rec...
Market PerformanceOn April 9, the Nifty Pharma index registered a sharp decline during early trading hours, dropping by 2 percent to 19,964.10. This continued a broader downward trend observed over the past six months, during which the index has fallen approximately 14 percent. All constituent st...
Market PerformanceThe Indian stock market declined on April 3, 2025, following the announcement of reciprocal tariffs by the United States. The Sensex fell by 322.08 points, or 0.42%, to close at 76,295.36. During intraday trading, the index saw a sharp decline of 809.89 points, hitting a low of ...
Market PerformanceOn April 2, U.S. President Donald Trump introduced broad reciprocal tariffs on trade partners, affecting multiple sectors globally. The announcement led to a decline in the Dow Jones Futures by over 1.5% and triggered volatility across international stock markets. The new tariff...
Open Free Trading & Demat Account
Trusted by 5.5 Lakh+ Investors
By proceeding, you agree to our Privacy Policy and Terms and Conditions.
Easy & quick
1. Register on SCORES portal
2. Mandatory details for filling complaints on SCORES
Name | PAN | Address | Mobile | Number | E-mail ID
3. Benefits
Effective Communication
Speedy redressal of the grievances
